1.
患者临床特征
Patient characteristics
| Characteristics | Maintenance/Consolidation chemotherapy (n=29) | Salvage chemotherapy (n=24) | P |
| ALP: alkaline phosphatase; LDH: lactate dehydrogenase; PS: performance status. | |||
| Age, yr, median (range) | 53 (40-70) | 57 (41-78) | 0.19 |
| Sex (n/%) | 0.74 | ||
| Male | 24 (82.8%) | 19 (72.9%) | |
| Female | 5 (17.2%) | 5 (20.8%) | |
| Age group (n/%) | 0.79 | ||
| ≥65 | 26 (89.7%) | 20 (83.3%) | |
| < 65 | 3 (10.3%) | 4 (16.7%) | |
| Stage (n/%) | 0.28 | ||
| Limit stage | 21 (72.4%) | 14 (58.3%) | |
| Extensive stage | 8 (27.6%) | 10 (41.7%) | |
| ECOG PS (n/%) | 0.35 | ||
| 0 | 0 (0.0%) | 1 (4.2%) | |
| 1 | 25 (86.2%) | 19 (79.2%) | |
| 2 | 4 (13.8%) | 3 (12.5%) | |
| 3 | 0 (0.0%) | 1 (4.2%) | |
| No. of metastatic sites (n/%) | 0.07 | ||
| 0 | 21 (72.4%) | 14 (58.3%) | |
| 1 | 8 (27.6%) | 7 (29.2%) | |
| 2 | 0 (0.0%) | 3 (12.5%) | |
| Elevated ALP level (n/%) | 4 (13.8%) | 3 (12.5%) | 0.89 |
| Decreased albumin (n/%) | 2 (7.0%) | 5 (20.8%) | 0.28 |
| Elevated LDH level (n/%) | 9 (31.0%) | 9 (37.5%) | 0.62 |